241 related articles for article (PubMed ID: 9771951)
21. Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.
Micozzi D; Carpi FM; Pucciarelli S; Polzonetti V; Polidori P; Vilar S; Williams B; Costanzi S; Vincenzetti S
Int J Biol Macromol; 2014 Feb; 63():64-74. PubMed ID: 24183806
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
[TBL] [Abstract][Full Text] [Related]
23. Human cytidine deaminase as an ex vivo drug selectable marker in gene-modified primary bone marrow stromal cells.
Eliopoulos N; Al-Khaldi A; Beauséjour CM; Momparler RL; Momparler LF; Galipeau J
Gene Ther; 2002 Apr; 9(7):452-62. PubMed ID: 11938460
[TBL] [Abstract][Full Text] [Related]
24. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
[TBL] [Abstract][Full Text] [Related]
25. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
26. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Momparler RL; Onetto-Pothier N; Momparler LF
Leuk Res; 1990; 14(9):755-60. PubMed ID: 1700231
[TBL] [Abstract][Full Text] [Related]
27. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
28. The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
Eda H; Ura M; F-Ouchi K; Tanaka Y; Miwa M; Ishitsuka H
Cancer Res; 1998 Mar; 58(6):1165-9. PubMed ID: 9515801
[TBL] [Abstract][Full Text] [Related]
29. Cellular differentiation, cytidine analogs and DNA methylation.
Jones PA; Taylor SM
Cell; 1980 May; 20(1):85-93. PubMed ID: 6156004
[TBL] [Abstract][Full Text] [Related]
30. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro.
Schröder JK; Kirch C; Flasshove M; Kalweit H; Seidelmann M; Hilger R; Seeber S; Schütte J
Leukemia; 1996 Dec; 10(12):1919-24. PubMed ID: 8946931
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
[TBL] [Abstract][Full Text] [Related]
32. Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.
Rattmann I; Kleff V; Sorg UR; Bardenheuer W; Brueckner A; Hilger RA; Opalka B; Seeber S; Flasshove M; Moritz T
Blood; 2006 Nov; 108(9):2965-71. PubMed ID: 16835384
[TBL] [Abstract][Full Text] [Related]
33. Identification of cytidine deaminase as inhibitor of granulocyte-macrophage colony formation.
Bøyum A; Løvhaug D; Seeberg E; Nordlie EM
Exp Hematol; 1994 Feb; 22(2):208-14. PubMed ID: 7507861
[TBL] [Abstract][Full Text] [Related]
34. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Vande Voorde J; Sabuncuoğlu S; Noppen S; Hofer A; Ranjbarian F; Fieuws S; Balzarini J; Liekens S
J Biol Chem; 2014 May; 289(19):13054-65. PubMed ID: 24668817
[TBL] [Abstract][Full Text] [Related]
35. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.
Beumer JH; Eiseman JL; Parise RA; Florian JA; Joseph E; D'Argenio DZ; Parker RS; Kay B; Covey JM; Egorin MJ
Cancer Chemother Pharmacol; 2008 Aug; 62(3):457-64. PubMed ID: 18008070
[TBL] [Abstract][Full Text] [Related]
36. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Grant S; Bhalla K; McCrady C
Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Chabot GG; Bouchard J; Momparler RL
Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
[No Abstract] [Full Text] [Related]
38. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.
Momparler RL; Laliberté J
Leuk Res; 1990; 14(9):751-4. PubMed ID: 1700230
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
40. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Chuang JC; Yoo CB; Kwan JM; Li TW; Liang G; Yang AS; Jones PA
Mol Cancer Ther; 2005 Oct; 4(10):1515-20. PubMed ID: 16227400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
